Literature DB >> 27392466

Evaluation of three risk assessment tools in discriminating fracture status among Chinese patients undergoing hemodialysis.

A-J Chang1, Q Ying2,3, X-N Chen1, W-M Wang1, N Chen1.   

Abstract

We evaluated three risk assessment tools, including bone mineral density (BMD) measurement by dual energy X-ray absorptiometry (DXA), osteoporosis self-assessment tool for Asians (OSTA), and fracture risk assessment tool (FRAX), for the prediction of fracture status among Chinese patients undergoing hemodialysis. All of the three assessment tools have a reasonable capability in discriminating fractures.
INTRODUCTION: Fractures are common in hemodialysis patients however insufficiently assessed. Our study aimed to assess the ability of three widely used tools [BMD, OSTA, and FRAX] to discriminate fracture status in patients with renal failure undergoing hemodialysis.
METHODS: We enrolled 136 hemodialysis patients in a tertiary teaching hospital setting. BMD was measured using DXA at the lumbar spine and the hip region. OSTA was calculated from weight and age. FRAX score was calculated based upon online availability. Discriminative abilities of BMD, OSTA, and FRAX in fracture status were analyzed by receiver operator characteristic (ROC) curves.
RESULTS: There were total 16 fractures (11.76 %) identified in 136 hemodialysis patients. BMD at any site (lumbar spine L1-L4, femoral neck, and total hip) was independently associated with fracture. Areas under the curves (AUC) of BMD (lumbar spine L1-L4, femoral neck, total hip), OSTA, FRAX1 (non-BMD model), and FRAX2 (BMD model) were 0.669 (95 % CI 0.583, 0.747), 0.708 ( 95 % CI 0.624, 0.783), 0.736 (95 % CI 0.654, 0.808), 0.686 (95 % CI 0.601, 0.763), 0.715 (95 % CI 0.631, 0.789), and 0.697 (95 % CI 0.613, 0.773), respectively. The differences of their performance were not significant.
CONCLUSIONS: All of the three risk assessment tools had the ability to discriminate fracture status among hemodialysis patients; FRAX BMD model did not improve the discriminative ability of BMD or FRAX non-BMD model alone.

Entities:  

Keywords:  Bone mineral density; FRAX; Fracture; Hemodialysis; OSTA

Mesh:

Year:  2016        PMID: 27392466     DOI: 10.1007/s00198-016-3690-8

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  39 in total

1.  Bone mineral acquisition in healthy Asian, Hispanic, black, and Caucasian youth: a longitudinal study.

Authors:  L K Bachrach; T Hastie; M C Wang; B Narasimhan; R Marcus
Journal:  J Clin Endocrinol Metab       Date:  1999-12       Impact factor: 5.958

2.  Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025.

Authors:  Russel Burge; Bess Dawson-Hughes; Daniel H Solomon; John B Wong; Alison King; Anna Tosteson
Journal:  J Bone Miner Res       Date:  2007-03       Impact factor: 6.741

3.  Increased risk of hip fracture among patients with end-stage renal disease.

Authors:  A M Alem; D J Sherrard; D L Gillen; N S Weiss; S A Beresford; S R Heckbert; C Wong; C Stehman-Breen
Journal:  Kidney Int       Date:  2000-07       Impact factor: 10.612

4.  The prevalence of hypovitaminosis D among US adults: data from the NHANES III.

Authors:  Ashraf Zadshir; Naureen Tareen; Deyu Pan; Keith Norris; David Martins
Journal:  Ethn Dis       Date:  2005       Impact factor: 1.847

5.  A comparison of hip fracture incidence among native Japanese, Japanese Americans, and American Caucasians.

Authors:  P D Ross; H Norimatsu; J W Davis; K Yano; R D Wasnich; S Fujiwara; Y Hosoda; L J Melton
Journal:  Am J Epidemiol       Date:  1991-04-15       Impact factor: 4.897

6.  The impact of a FRAX-based intervention threshold in Turkey: the FRAX-TURK study.

Authors:  Sansin Tuzun; Nurten Eskiyurt; Ulku Akarirmak; Merih Saridogan; Helena Johansson; Eugene McCloskey; John A Kanis
Journal:  Arch Osteoporos       Date:  2012       Impact factor: 2.617

7.  Economic burden of cardiovascular events and fractures among patients with end-stage renal disease.

Authors:  Quan V Doan; Michelle Gleeson; John Kim; Rohit Borker; Robert Griffiths; Robert W Dubois
Journal:  Curr Med Res Opin       Date:  2007-07       Impact factor: 2.580

8.  Hypovitaminosis D prevalence and determinants among African American and white women of reproductive age: third National Health and Nutrition Examination Survey, 1988-1994.

Authors:  Shanna Nesby-O'Dell; Kelley S Scanlon; Mary E Cogswell; Cathleen Gillespie; Bruce W Hollis; Anne C Looker; Chris Allen; Cindy Doughertly; Elaine W Gunter; Barbara A Bowman
Journal:  Am J Clin Nutr       Date:  2002-07       Impact factor: 7.045

9.  High rates of death and hospitalization follow bone fracture among hemodialysis patients.

Authors:  Francesca Tentori; Keith McCullough; Ryan D Kilpatrick; Brian D Bradbury; Bruce M Robinson; Peter G Kerr; Ronald L Pisoni
Journal:  Kidney Int       Date:  2013-07-31       Impact factor: 10.612

10.  Clinician's Guide to Prevention and Treatment of Osteoporosis.

Authors:  F Cosman; S J de Beur; M S LeBoff; E M Lewiecki; B Tanner; S Randall; R Lindsay
Journal:  Osteoporos Int       Date:  2014-08-15       Impact factor: 4.507

View more
  3 in total

1.  Predictors of bone fractures in a single-centre cohort of hemodialysis patients: a 2-year follow-up study.

Authors:  Ludmila Brunerová; Renata Lažanská; Petr Kasalický; Jana Verešová; Jana Potočková; Alena Fialová; Ivan Rychlík
Journal:  Int Urol Nephrol       Date:  2018-08-16       Impact factor: 2.370

2.  Prevalence and predictors of asymptomatic vertebral fracture in patients with end-stage renal disease.

Authors:  Sasipim Jirasirirak; Sinee Disthabanchong; Boonsong Ongphiphadhanakul; Sakda Arj-Ong Vallibhakara; Hataikarn Nimitphong
Journal:  Heliyon       Date:  2022-03-23

3.  Predicting the intervention threshold for initiating osteoporosis treatment among postmenopausal women in China: a cost-effectiveness analysis based on real-world data.

Authors:  L Cui; T He; Y Jiang; M Li; O Wang; R Jiajue; Y Chi; Q Xu; X Xing; W Xia
Journal:  Osteoporos Int       Date:  2019-11-21       Impact factor: 4.507

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.